Positive Phase II lymphoma data for Genmab/GSK's ofatumumab
This article was originally published in Scrip
Executive Summary
Genmab has reported positive top-line Phase II results for its monoclonal antibody, Arzerra (ofatumumab), when used in combination with salvage chemotherapy to treat second-line aggressive lymphoma.